Eldar Kim

Gründer bei MSM Protein Technologies, Inc.

Health Technology

Profil

Eldar Kim is the founder of MSM Protein Technologies, Inc. He held the title of Director & Chief Scientific Officer since the company's founding in 2005.

Aktive Positionen von Eldar Kim

Unternehmen	Position	Beginn
MSM Protein Technologies, Inc. MSM Protein Technologies, Inc. Pharmaceuticals: MajorHealth Technology MSM Protein Technologies is an early drug development company that specializes in antibody drug discovery against integral membrane proteins. MSM Protein Technologies is based in Waltham, MA and was founded in 2005 by Davis Farmer, Eldar Kim, and David Kreimer. The private company has a solid record of successful partnerships with big pharma companies in drug discovery and development programs. The company's pipeline includes a number of first-in-class pre-clinical stage antibodies targeting several GPCRs, mainly focused on immunologic and oncologic diseases such as blood cancers, solid tumors, autoimmune diseases, and respiratory diseases.	Gründer	01.01.2005

Alle aktiven Positionen von Eldar Kim

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Eldar Kim im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
MSM Protein Technologies, Inc. MSM Protein Technologies, Inc. Pharmaceuticals: MajorHealth Technology MSM Protein Technologies is an early drug development company that specializes in antibody drug discovery against integral membrane proteins. MSM Protein Technologies is based in Waltham, MA and was founded in 2005 by Davis Farmer, Eldar Kim, and David Kreimer. The private company has a solid record of successful partnerships with big pharma companies in drug discovery and development programs. The company's pipeline includes a number of first-in-class pre-clinical stage antibodies targeting several GPCRs, mainly focused on immunologic and oncologic diseases such as blood cancers, solid tumors, autoimmune diseases, and respiratory diseases.	Health Technology